Scientists in Spain have now developed small particles with the ability to encapsulate growth factors when implanted in the brain, which could ultimately reverse the effects of these diseases by spurring the growth of new, healthy neurons.
Massachusetts General Hospital investigator Rudy Tanzi has created a new "Alzheimer's-in-a-dish" approach to growing brain cells that he claims provides clear proof of the much-debated amyloid hypothesis as well as a solid target for the disease. And now he reportedly plans to race ahead with his new research process to find a potential megablockbuster drug that can stop the disease in its tracks.
German drug developer Probiodrug is looking to go public on the Amsterdam exchange, seeking funds to advance its pipeline of treatments for Alzheimer's disease as more and more European biotechs set sights on IPOs.
Avanir's combinatorial approach to calming dementia-related outbursts among Alzheimer's patients caught the attention of Wall Street on Monday morning. The biotech touted midstage data demonstrating that a match of two treatments--a generic cough suppressant and a long-approved treatment for irregular heartbeats--significantly reduced the level of agitation among the patients in the study.
Eli Lilly's Alzheimer's imaging agent, Amyvid, can't get very far sales-wise without coverage from the Center for Medicare and Medicaid Services (CMS). And as per a September decision, that's something it doesn't have. Now, however, it's fighting back, funding litigation it couldn't file itself.
Researchers have used a new drug compound to successfully reverse brain deficits caused by Alzheimer's in animal models. The compound, TC-2153, inhibits the negative effects of a protein called striatal-enriched tyrosine phosphatase--a process that scientists found is key to restoring functions in learning and memory.
This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.
Jeffrey Cummings is directing one of the few early-stage studies underway on an Alzheimer's therapy. And now that he's scanned the records of clinicaltrials.gov, he's acutely aware of just how small his chosen field is.
Promising to use its technology to enhance the efficacy and safety of currently approved Alzheimer's drugs, Chase Pharmaceuticals says it has now added $21 million in new venture cash.
Merck may lead the industry in developing a new BACE inhibitor for Alzheimer's, but AstraZeneca feels that it has a shot at blockbuster glory in the field as well. And now the pharma giant wants to rope a partner in to share the potential rewards, as well as the high level of risk involved--if not just take over the whole thing.